Long-term changes in bone mineral density after switching to a protease inhibitor monotherapy in HIV-infected subject
Although some clinical trials have studied the impact of treatments on bone mineral density (BMD), scarce data are available about the impact of protease inhibitor (PI) monotherapies on BMD. The aim of this study was to evaluate changes in BMD in patients after one, two, or three years of a PI monotherapy. This study included 46 HIV-infected patients who switched from a conventional triple antiretroviral strategy to a monotherapy with lopinavir/ritonavir (LPV/r) or darunavir/ritonavir (DRV/r) for one (one-year group, n=16), two (two-year group, n=20), and three (three-year group, n=10) years. BMD was assessed by dual-energy X-ray absorptiometry (DXA). The median percentage of change in total femur BMD was 0.20% after one, 0.79% after two, and -0.31% after three years. The change in lumbar spine was -0.08%, -0.14%, and 0.50% % after the same years. No significant differences were found when patients were classified regarding the type of PI and whether or not had previously received PI or tenofovir. However, patients who interrupted tenofovir or those who started with DRV/r had a higher BMD increment. Patients who had taken non-nucleoside reverse transcriptase inhibitors previously decreased BMD when started PIs. Monotherapy treatment with ritonavir-boosted protease inhibitors (both LPV/r and DRV/r) during one, two, or three years leads to the stabilization of BMD in HIV-infected patients with long-term virological suppression. Larger studies are necessary to compare the effect of starting or withdrawing PIs on BMD.
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2015 |
|---|---|
| Erschienen: |
2015 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:38 |
|---|---|
| Enthalten in: |
The new microbiologica - 38(2015), 2 vom: 17. Apr., Seite 193-9 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Negredo, Eugènia [VerfasserIn] |
|---|
| Themen: |
2494G1JF75 |
|---|
| Anmerkungen: |
Date Completed 13.08.2015 Date Revised 27.05.2015 published: Print-Electronic Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM24866784X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM24866784X | ||
| 003 | DE-627 | ||
| 005 | 20231224151914.0 | ||
| 007 | tu | ||
| 008 | 231224s2015 xx ||||| 00| ||eng c | ||
| 028 | 5 | 2 | |a pubmed24n0828.xml |
| 035 | |a (DE-627)NLM24866784X | ||
| 035 | |a (NLM)25938744 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Negredo, Eugènia |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Long-term changes in bone mineral density after switching to a protease inhibitor monotherapy in HIV-infected subject |
| 264 | 1 | |c 2015 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a Date Completed 13.08.2015 | ||
| 500 | |a Date Revised 27.05.2015 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Although some clinical trials have studied the impact of treatments on bone mineral density (BMD), scarce data are available about the impact of protease inhibitor (PI) monotherapies on BMD. The aim of this study was to evaluate changes in BMD in patients after one, two, or three years of a PI monotherapy. This study included 46 HIV-infected patients who switched from a conventional triple antiretroviral strategy to a monotherapy with lopinavir/ritonavir (LPV/r) or darunavir/ritonavir (DRV/r) for one (one-year group, n=16), two (two-year group, n=20), and three (three-year group, n=10) years. BMD was assessed by dual-energy X-ray absorptiometry (DXA). The median percentage of change in total femur BMD was 0.20% after one, 0.79% after two, and -0.31% after three years. The change in lumbar spine was -0.08%, -0.14%, and 0.50% % after the same years. No significant differences were found when patients were classified regarding the type of PI and whether or not had previously received PI or tenofovir. However, patients who interrupted tenofovir or those who started with DRV/r had a higher BMD increment. Patients who had taken non-nucleoside reverse transcriptase inhibitors previously decreased BMD when started PIs. Monotherapy treatment with ritonavir-boosted protease inhibitors (both LPV/r and DRV/r) during one, two, or three years leads to the stabilization of BMD in HIV-infected patients with long-term virological suppression. Larger studies are necessary to compare the effect of starting or withdrawing PIs on BMD | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Bone density | |
| 650 | 4 | |a Demineralization | |
| 650 | 4 | |a Densitometry | |
| 650 | 4 | |a HIV | |
| 650 | 4 | |a Protease inhibitor | |
| 650 | 7 | |a Anti-HIV Agents |2 NLM | |
| 650 | 7 | |a HIV Protease Inhibitors |2 NLM | |
| 650 | 7 | |a Lopinavir |2 NLM | |
| 650 | 7 | |a 2494G1JF75 |2 NLM | |
| 650 | 7 | |a Ritonavir |2 NLM | |
| 650 | 7 | |a O3J8G9O825 |2 NLM | |
| 700 | 1 | |a Bonjoch, Anna |e verfasserin |4 aut | |
| 700 | 1 | |a Puig, Jordi |e verfasserin |4 aut | |
| 700 | 1 | |a Echeverría, Patricia |e verfasserin |4 aut | |
| 700 | 1 | |a Estany, Carla |e verfasserin |4 aut | |
| 700 | 1 | |a Santos, José R |e verfasserin |4 aut | |
| 700 | 1 | |a Moltó, José |e verfasserin |4 aut | |
| 700 | 1 | |a Pérez-Álvarez, Nuria |e verfasserin |4 aut | |
| 700 | 1 | |a Ornelas, Arelly |e verfasserin |4 aut | |
| 700 | 1 | |a Clotet, Bonaventura |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The new microbiologica |d 1993 |g 38(2015), 2 vom: 17. Apr., Seite 193-9 |w (DE-627)NLM074818287 |x 1121-7138 |7 nnns |
| 773 | 1 | 8 | |g volume:38 |g year:2015 |g number:2 |g day:17 |g month:04 |g pages:193-9 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 38 |j 2015 |e 2 |b 17 |c 04 |h 193-9 | ||